Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LTX-02
- Development stage
- Preclinical
- Lead developer
- Acura Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**LTX-02** is an early-stage, immediate-release oral fixed-dose formulation of **oxycodone hydrochloride + acetaminophen** developed using Acura's proprietary **LIMITx** technology. The product is intended for pain treatment while reducing risks from excess oral tablet ingestion. LIMITx incorporates buffering and release-modifying excipients designed to reduce gastric-acid-dependent release and systemic absorption of opioid active ingredient when multiple tablets are swallowed. Oxycodone provides opioid analgesia primarily through agonism of the mu-opioid receptor, while acetaminophen provides complementary non-opioid analgesic activity. Acura licensed exclusive United States commercialization rights for LTX-02 to Abuse Deterrent Pharma.
- Other names
- oxycodone + acetaminophenLIMITx oxycodone + acetaminophen
02
Targets
KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)
Beyond the preview
Go deeper on LTX-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LTX-02.